Table 2.
Effect of early therapy on treatment targets at 1 year in children with Crohn’s disease.
| Outcome at 1 year, [%] | Early anti-TNF therapy [n = 135; 41%] |
No early anti-TNF therapy [n = 196; 59%] |
Total [n = 331] |
p-value |
|---|---|---|---|---|
| Remission | 90/129 [70] | 128/185 [69] | 218/314 [69] | 0.91 |
| NCR | 74/121 [61] | 75/162 [46] | 149/283 [53] | 0.01 |
| NFR | 29/76 [38] | 27/101 [27] | 56/177 [32] | 0.11 |
| SFR | 85/130 [65] | 116/185 [63] | 201/315 [64] | 0.63 |
| SSFR | 40/131 [31] | 38/185 [21] | 78/316 [25] | 0.04 |
| SSFR* | 39/131 [30] | 26/185 [14] | 65/316 [21] | <0.001 |
| SSFR* from 6 monthsa | 50/129 [39] | 38/183 [21] | 88/312 [28] | <0.001 |
| SFMI | 117/130 [90] | 154/185 [83] | 271/315 [86] | 0.09 |
| SSFMI | 92/127 [72] | 86/177 [49] | 178/304 [59] | <0.001 |
| SSFMI* | 88/127 [69] | 58/177 [33] | 146/304 [48] | <0.001 |
| SSFMI* from 6 monthsb | 98/127 [77] | 66/179 [37] | 164/306 [54] | <0.001 |
| Endoscopic inflammation as estimated by MINI-index | 0.50 | |||
| Mucosal healing | 47/71 [66] | 42/74 [57] | 89/145 [61] | |
| Mild inflammation | 13/71 [18] | 17/74 [23] | 30/145 [21] | |
| Moderate/severe inflammation | 11/71 [16] | 15/74 [20] | 26/145 [18] |
Varying denominators are the result of different starting points for certain outcomes, the underlying criteria for outcomes and missing data.
TNF, tumour necrosis factor; CRP, C-reactive protein; FC, faecal calprotectin; NCR, normal CRP remission [remission with CRP <0.5 mg/dl]; NFR, normal FCP remission [remission with faecal calprotectin <250 μg/g]; SFR, steroid-free remission; SSFR, sustained steroid-free remission; SSFR*, SSFR without treatment intensification, SFMI, steroid-free mild or inactive disease; SSFMI, sustained SFMI; SSFMI*, SSFMI without treatment intensification; MINI-index, mucosal inflammation non-invasive index.
aDefined as being continuous steroid-free remission without treatment intensification from 6 months after diagnosis up to the time-point of assessment.
bDefined as being in continuous steroid-free mild or inactive disease without treatment intensification from 6 months after diagnosis up to the time point of assessment.